Certain breast cancer patients may benefit from combined HER2 targeted therapy without chemotherapy
HOUSTON – (April 8, 2013) – Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine – at least for a certain population of women.
In a report that appears online today in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments that zero in on the breast cancer cells ...